Nabi (NABI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Nabi (NABI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: R. E. Simpson who wrote (330)	11/1/2005 12:49:03 PM
From: Extra Pale	Read Replies (1) of 354

Nabi cc, limited notes: - titer rates of antibodies higher in confirmatory than in initial phase 3 - indicated that issue appears to be 'quality' of antibodies - staphvax studies accounted for 70% of last quarter's R&D burn - one question asked if vaccine facilities could converted for other vaccine manufacture, which I assume was indirect question regarding avian flu vaccine production. answer was that facility is flexible for nabi vaccine candidates - unclear to me how to read response as to capability to make non-nabi vaccines. - couple of questions about going forward options, such as partnering or sale of company. non response of course. totally at a loss as to why phase 3 failed so miserably after 7years of prior study.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next